Saxenda and Wegovy are both approved for chronic weight management, but they contain different active ingredients, liraglutide and semaglutide, with Wegovy's once-weekly dosing and stronger trial results making it the more commonly prescribed of the two.

Ozempic and Mounjaro are both approved for type 2 diabetes, but they contain different active ingredients, semaglutide and tirzepatide, with Mounjaro's dual mechanism showing greater average weight loss in head-to-head trial data.

Trulicity and Ozempic are both once-weekly GLP-1 medications for type 2 diabetes, but they contain different active ingredients, and real-world data suggests Ozempic tends to produce more weight loss and fewer GI side effects than Trulicity.

Head-to-head trial data shows tirzepatide produces greater average weight loss than semaglutide, driven by its dual GLP-1/GIP mechanism, though semaglutide has a longer track record and broader cardiovascular data.

Wegovy and Zepbound are both approved for chronic weight management, but Zepbound has shown greater average weight loss in head-to-head data and carries an additional approval for obstructive sleep apnea that Wegovy does not.